Pharmacologic Options to Prevent Postoperative Ileus

Center for Drug Policy, Partner's Healthcare, Needham, MA 02494, USA.
Annals of Pharmacotherapy (Impact Factor: 2.92). 07/2009; 43(9):1474-85. DOI: 10.1345/aph.1M121
Source: PubMed

ABSTRACT To summarize the evidence on pharmacologic options in preventing postoperative ileus (POI).
The Cochrane Database of Reviews and OVID databases and Food and Drug Administration (FDA) Web site were searched (1950-April 2009) using the term postoperative ileus.
Meta-analyses and randomized controlled trials were included for review. The FDA Web site was searched for clinical reviews and label information for drugs indicated for the prevention of POI.
Three meta-analyses, 2 on gum-chewing and 1 on alvimopan, and 18 clinical trials were identified. Only gum chewing and alvimopan were effective in preventing POI. Gum chewing reduced the time to first flatus and bowel movement (weighted mean difference 21h; p = 0.0006 and 33h; p = 0.0002, respectively). In one meta-analysis, gum chewing significantly reduced length of stay (LOS) by 2.4 days (p < 0.00001) but this was not replicated in the second meta-analysis. Alvimopan shortened the time to reach a composite endpoint of solid food intake, plus/minus flatus, and bowel movement (93 vs 105 h; p < 0.001). A higher incidence of myocardial infarction was observed in a 12-month study of alvimopan for the treatment of opioid-induced bowel dysfunction, but not in studies in patients undergoing bowel resection. Alvimopan decreased the time to written hospital discharge order (hazard ratio 1.35; p < 0.01), while the significance of a reduction in LOS (0.2-1.3 days) was not reported.
Gum chewing and alvimopan are effective in preventing POI, but given safety concerns and higher cost with alvimopan, gum chewing may be preferred.

Download full-text


Available from: Elissa V Klinger, Jan 05, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Our previous study has shown that mangiferin (MGF), a glucosylxanthone from Mangifera indica, exerts gastrointestinal prokinetic action involving a cholinergic mechanism. Postoperative ileus (POI) is a temporary disturbance in gastrointestinal motility following surgery, and intestinal inflammatory response plays a critical role in the pathogenesis of POI. The present study investigated to know whether MGF having anti-inflammatory and prokinetic actions can ameliorate the intestinal inflammation and impaired gastrointestinal transit seen in the mouse model of POI. Experimental POI was induced in adult male Swiss mice by standardized small intestinal manipulation (IM). Twenty-four hours later, gastrointestinal transit was assessed by charcoal transport. MGF was administered orally 1 h before the measurement of GIT. To evaluate the inflammatory response, plasma levels of proinflammatory cytokines TNF-α, IL-1β, IL-6, and chemokine MCP-1, and the myeloperoxidase activity, nitrate/nitrite level, and histological changes of ileum were determined in mice treated or not with MGF. Experimental POI in mice was characterized by decreased gastrointestinal transit and marked intestinal and systemic inflammatory response. MGF treatment led to recovery of the delayed intestinal transit induced by IM. MGF in ileum significantly inhibited the myeloperoxidase activity, a marker of neutrophil infiltration, and nitrate/nitrite level and reduced the plasma levels of TNF-α, IL-1β, IL-6, and MCP-1 as well. MGF treatment ameliorates the intestinal inflammatory response and the impaired gastrointestinal motility in the mouse model of POI.
    Archiv für Experimentelle Pathologie und Pharmakologie 02/2015; DOI:10.1007/s00210-015-1095-4 · 2.36 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: All patients develop postoperative ileus (POI) after major abdominal surgery, with approx-imately 10% developing a more severe form of prolonged ileus. POI represents the single largest factor influencing length of stay after abdominal surgery and has the great impli-cations for patients and resource use in health care. New methods to treat and decrease the duration of POI are therefore of great importance. Up to the year 2000, several pharmacologic agents had been studied to prevent POI; however, none of these agents were effective enough to become part of routine established practice. Over the past decade, significant progress has been made treating POI pharmacologically. This article outlines the different pharmacologic options that exist for POI, with emphasis on the research during the past decade and future perspectives. Semin Colon Rectal Surg xx:xxx © 2010 Published by Elsevier Inc. A ll patients undergoing bowel resection develop an oblig-atory period of postoperative ileus (POI). 14-17 POI is characterized by a transient cessation of bowel function with a variable reduction in motility sufficient to prevent effective transit of intestinal contents. 18 POI is the single most impor-tant determinant of length of stay (LOS) after abdominal surgery and thus has significant implications for individual patients and hospital resource use. Surgeons have discussed POI for more than 2 centu-ries. 19,20 In 1906, Finney divided POI into 3 subgroups ac-cording to pathophysiology: mechanical, septic, and ady-namic. 21 After a century of debate a consensus conference in 2006 proposed a definition of POI as "transient cessation of coordinated bowel motility after surgical intervention, which prevents effective transit of intestinal contents or tolerance of oral intake." 18 Primary POI was defined as such cessation occurring in the absence of any precipitating complication, whereas secondary POI was defined as that occurring in the presence of a precipitating complication (anastomotic leak, pneumonia, etc.)." Patients undergoing major abdominal surgery are at highest risk for developing POI. Clinically, POI is characterized by an inability to tolerate a solid diet, delayed passage of flatus and formed stool, pain, and abdominal distention, nausea, vomiting, and accumula-tion of gas or fluids in the intestine. 22,23 Numerous surgical, anesthetic, and postoperative strategies have been explored to limit POI. These include laparoscopic surgery, epidural anesthesia, opioid-sparing regimens, early feeding, and early ambulation. Often several interventions are combined into a "fast track protocol" that has been collectively shown to fur-ther decrease POI and LOS. 24 Regarding pharmacologic treatment, multiple agents, including albumin, 25 -block-ers, 26 erythromycin, 11 gum chewing, 27-30 and metoclopra-mide, 6 have been studied in this setting. Two new drugs, both peripheral -opioid receptor antagonists, methylnal-trexone and alvimopan, have recently been evaluated for POI. The objective of this article is to highlight the pharma-cologic treatment of POI, with a focus on past and present research.
    Seminars in Colon [amp ] Rectal Surgery 05/2010; DOI:10.1053/j.scrs.2010.05.006
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: All patients undergoing bowel resection experience postoperative ileus, a transient cessation of bowel motility that prevents effective transit of intestinal contents or tolerance of oral intake, to varying degrees. An anesthesiologist plays a critical role, not only in the initiation of surgical anesthesia, but also with the selection and transition to effective postoperative analgesia regimens. Attempts to reduce the duration of postoperative ileus have prompted the study of various preoperative, perioperative, and postoperative regimens to facilitate gastrointestinal recovery. These include modifiable variables such as epidural anesthesia and analgesia, opioid-sparing anesthesia and analgesia, fluid restriction, colloid versus crystalloid combinations, prokinetic drugs, and use of the new peripherally acting mu-opioid receptor (PAM-OR) antagonists. Review and appropriate adaptation of these multiple modifiable interventions by anesthesiologists and their surgical colleagues will facilitate implementation of a best-practice management routine for bowel resection procedures that will benefit the patient and the healthcare system.
    01/2011; 2011:976904. DOI:10.4061/2011/976904